Wayne Kuznar
Authored Items
By Wayne Kuznar
Articles
At the 12th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2022, held October 19-21, 2022, in New York City, a panel of experts from Upstream Partners discussed the current state of value-based agreements (VBAs) in pharma and what lies ahead. The session was moderated by Burt Zweigenhaft, PhD, DLitt, Executive Director and Co-Founder of AVBCC. Read More ›
By Wayne Kuznar
Articles
With better insights into the biology of cancer and other diseases, genetic medicine is entering “a whole new ballgame,” said Scott Gottlieb, MD, Former FDA Commissioner, during the keynote session at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021. Read More ›
By Wayne Kuznar
Articles
Community-based providers remain at the core of the oncology care delivery system. A panel moderated by Barbara McAneny, MD, Chief Executive Officer, New Mexico Oncology Hematology Consultants, Albuquerque, at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021 explored the road ahead for community practices in terms of balancing value and delivering optimal access to care for patients. Read More ›
By Wayne Kuznar
Articles
Many innovative therapies in oncology have made it to market recently, with a wealth of agents that are currently on the verge of FDA approval. Read More ›
By Wayne Kuznar
Articles
The success of oncology support services developed by pharmaceutical manufacturers depends on tailoring programs that meet the needs of their specific patient populations, said panelists at a roundtable discussion on patient centricity and connectivity in oncology support and HUB services. Read More ›
By Wayne Kuznar
Articles
Oncologic drug pricing is being transformed with greater value in mind. At the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021, a panel led by moderator William McGivney, PhD, Managing Principal, McGivney Global Advisors, Wayne, PA, discussed innovation in drug pricing, how the current rebate system supports higher drug costs, balancing new interventions with profits, and the implications of drug price negotiations being considered in Congress. Read More ›
By Wayne Kuznar
Articles
The use of telehealth in the fee-for-service program surged by more than 4000% during the first 6 months of the COVID-19 pandemic. Read More ›
By Wayne Kuznar
Articles
Currently, 31 biosimilar products have been approved by the FDA, 20 of which have been launched in the United States. Read More ›